title: Autopsy findings after intracranial thrombectomy for acute ischemic stroke: a clinicopathologic study of 5 patients.
abstract: OBJECTIVE
  Endovascular thrombectomy is an increasingly used treatment for arterial occlusion in acute stroke. Various devices (including most extensively the Mechanical Embolus Removal in Cerebral Ischemia [MERCI] Retriever device) have been used for this.
  
  
  METHODS
  We review the neuropathologic findings in 5 patients (age range, 59 to 87 years) who died acutely or as late as 38 days after procedures using the MERCI (4 patients) and Penumbra (1 patient) devices were carried out to remove thromboemboli from the middle cerebral artery. Partial recanalization was achieved by thrombectomy in all 5 patients.
  
  
  RESULTS
  All patients showed extensive cerebral infarcts, 3 of 5 with clinical hemorrhagic transformations of the infarct or frank intraparenchymal hemorrhage after thrombectomy; in 1 case, this was judged to be at least partly on the basis of concomitant hypertensive microvascular disease. With 1 exception, basal arteries examined in detail by immunohistochemistry showed prominent, although usually nonocclusive (and generally nonulcerated), atheromata, often with significant luminal stenosis. One patient showed a subintimal dissection with resultant occlusion of the middle cerebral artery.
  
  
  CONCLUSIONS
  In this highly selected group of patients, the vascular pathological abnormalities affecting basal arteries were variable, but complicated atherosclerosis was a common finding. Extensive irreversible brain necrosis before therapeutic procedures may have contributed to deaths.
authors.affiliation: Department of Pathology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
authors.forename: Nicole S
authors.initials: NS
authors.lastname: Yin
authors.forename: Sebastian
authors.initials: S
authors.lastname: Benavides
authors.forename: Sidney
authors.initials: S
authors.lastname: Starkman
authors.forename: David S
authors.initials: DS
authors.lastname: Liebeskind
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Saver
authors.forename: Noriko
authors.initials: N
authors.lastname: Salamon
authors.forename: Reza
authors.initials: R
authors.lastname: Jahan
authors.forename: Gary R
authors.initials: GR
authors.lastname: Duckwiler
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tateshima
authors.forename: Fernando
authors.initials: F
authors.lastname: Vinuela
authors.forename: Paul M
authors.initials: PM
authors.lastname: Vespa
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Chute
authors.forename: Harry V
authors.initials: HV
authors.lastname: Vinters
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D005260:Female; D006801:Humans; D020767:Intracranial Thrombosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017131:Thrombectomy / Q000401:mortality; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
chemical_list: D010959:Tissue Plasminogen Activator